Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mei-Lu Chen"'
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Changes of cell types based on (a) MCP-Counter and (b) Danaher module with post- vs pre-treatment samples. All tests were performed by non-parametric Wilcoxon test.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28341cb739677a8a98ca9b90ac8d5e42
https://doi.org/10.1158/1078-0432.22489661.v1
https://doi.org/10.1158/1078-0432.22489661.v1
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
CONSORT diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022e981f256a0e01baaf11ad71664e1e
https://doi.org/10.1158/1078-0432.22489667
https://doi.org/10.1158/1078-0432.22489667
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Volcano plots of differentially expressed genes of different clinical scenarios (a) partial responders vs non-partial responders (b) progression-free survival longer vs shorter than 6 months (c) post- and pre-treatment samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edf15c742ebf3b4fdea42c84e8c8376
https://doi.org/10.1158/1078-0432.22489658
https://doi.org/10.1158/1078-0432.22489658
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ea343b0d03f091abaeba042b894f40
https://doi.org/10.1158/1078-0432.22489664
https://doi.org/10.1158/1078-0432.22489664
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Supplementary Table 1a. Differentially expressed genes between Post-treatment vs Pre-treatment; Supplementary Table 1b. Differentially expressed genes between Responders vs Nonresponders; Supplementary Table 1c. Differentially expressed genes between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::787287a6c1a66c3d58fa34daa6fa9c99
https://doi.org/10.1158/1078-0432.22489655.v1
https://doi.org/10.1158/1078-0432.22489655.v1
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Decision on Final Phase II dose; Guidelines combination dose level adjustments in the phase Ib phase; Schema for dose adjustments if more than 2 patients have DLT; Definitions of DLT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::870453c39ca702cea3312c7fc1e92875
https://doi.org/10.1158/1078-0432.22489670.v1
https://doi.org/10.1158/1078-0432.22489670.v1
Autor:
Chueh-Chuan Yen, Ann-Lii Cheng, Ting-Fang Kung, Meng-Chi Hsu, Mei-Lu Chen, Jhe-Cyuan Guo, San-Chi Chen, Chih-Wei Yu, Koping Chang, Jen-Chieh Lee, Ruey-Long Hong, Chia-Lang Hsu, Tom Wei-Wu Chen
Purpose:Satisfactory treatment options for advanced leiomyosarcoma and liposarcoma are limited. The LEADER study (NCT03526679) investigated the safety and efficacy of lenvatinib plus eribulin.Patients andMethods:LEADER is a multicenter phase Ib/II st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fe5c79bc9ccbc717144668afed8f75e
https://doi.org/10.1158/1078-0432.c.6533006
https://doi.org/10.1158/1078-0432.c.6533006
Autor:
Tom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, Jen-Chieh Lee, Koping Chang, Chih-Wei Yu, San-Chi Chen, Jhe-Cyuan Guo, Mei-Lu Chen, Meng-Chi Hsu, Ting-Fang Kung, Ann-Lii Cheng, Chueh-Chuan Yen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(23)
Purpose: Satisfactory treatment options for advanced leiomyosarcoma and liposarcoma are limited. The LEADER study (NCT03526679) investigated the safety and efficacy of lenvatinib plus eribulin. Patients and Methods: LEADER is a multicenter phase Ib/I
Autor:
Tom Wei-Wu Chen, Chueh-Chuan Yen, Ruey-Long Hong, Jen-Chieh Lee, Koping Chang, Chih-Wei Yu, San-Chi Chen, Mei-Lu Chen, Meng-Chi Hsu, Ting-Fang Kung, Ann-Lii Cheng
Publikováno v:
Journal of Clinical Oncology. 40:11506-11506
11506 Background: There are limited treatment options for advanced LPS and LMS, the two most common histologies in soft tissue sarcoma. Patients (pts) treated with E had an improved overall survival (OS) compared to dacarbazine but with an unsatisfac
Autor:
Chih-Wei Yu, San-Chi Chen, Chueh-Chuan Yen, Jen-Chieh Lee, Meng-Chi Hsu, Hsin-Fang Chang, Ting-Fang Kung, Ruey-Long Hong, Mei-Lu Chen, Tom Wei-Wu Chen, Jhe-Cyuan Guo
Publikováno v:
Journal of Clinical Oncology. 38:11507-11507
11507 Background: For advanced LPS and LMS, the two most common histologies in soft tissue sarcoma, there are limited treatment options that readily balance efficacy and toxicity. Patients (pts) treated with E had an improved median overall survival